BiotechTube

PF-05221304

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Normal Healthy

Conditions

Normal Healthy

Trial Timeline

Aug 1, 2016 → Mar 1, 2017

NCT ID
NCT02871037

About PF-05221304

PF-05221304 is a phase 1 stage product being developed by Pfizer for Normal Healthy. The current trial status is completed. This product is registered under clinical trial identifier NCT02871037. Target conditions include Normal Healthy.

What happened to similar drugs?

4 of 6 similar drugs in Normal Healthy were approved

Approved (4) Terminated (2) Active (2)
✅DonepezilEisaiApproved
✅Eybelis ophthalmic solution 0.002%Santen PharmaceuticalApproved
✅cyclosporine micro-emulsionNovartisApproved
✅Aspirin 100 mg + PlaceboBayerApproved
🔄Gadopentetate dimeglumine (Magnevist)BayerPhase 3
🔄lixivaptan + placeboBiogenPhase 3

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT03309202Phase 1Completed
NCT02871037Phase 1Completed

Competing Products

20 competing products in Normal Healthy

See all competitors
ProductCompanyStageHype Score
RoxadustatAstellas PharmaPhase 1
29
DonepezilEisaiApproved
43
eribulin mesylateEisaiPhase 2
35
Lurasidone HClSumitomo PharmaPhase 1
29
Eybelis ophthalmic solution 0.002%Santen PharmaceuticalApproved
39
TriptorelinMerckPre-clinical
26
Temozolomide + VorinostatMerckPhase 2
35
LDE225NovartisPhase 1
29
LDK378NovartisPhase 1
29
cyclosporine micro-emulsionNovartisApproved
35
LDK378NovartisPhase 1
29
LEE011NovartisPhase 1
29
LEE011NovartisPhase 1
29
mycophenolate mofetilRochePhase 1
29
filgrastimAmgenPre-clinical
26
PF-06423264PfizerPhase 1
21
BMS-933043 + Placebo matching with BMS-933043 + Antacid Buffer Predose SolutionBristol Myers SquibbPhase 1
29
tolebrutinibSanofiPhase 1
29
Venglustat (GZ402671)SanofiPhase 1
29
RilzabrutinibSanofiPhase 1
29